USD $ 5,700.00
Introduction This analysis examines the historical and forecast performance for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wit...
|
USD $ 3,800.00
Introduction Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences' cethromycin, along with Sanofi-Aventis' Ketek, is a ketolide, a second-generation class of macrolid...
|
USD $ 5,700.00
Introduction This analysis examines the historical and forecast performance for Allergan in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ...
|
USD $ 5,700.00
Introduction This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ...
|
USD $ 5,695.00
Introduction This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with...
|
|
|
USD $ 5,695.00
Introduction This analysis examines the historical and forecast performance for Astellas in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w...
|
USD $ 2,875.00
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches a...
|
USD $ 2,875.00
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches a...
|
|
|
USD $ 3,800.00
Introduction This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An i...
|
USD $ 3,800.00
Introduction This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An i...
|
USD $ 5,700.00
Introduction This analysis examines the historical and forecast performance for Bayer Schering in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wi...
|
USD $ 7,600.00
Introduction 'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins...
|
USD $ 5,695.00
Introduction This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance...
|
|
|
|
|
USD $ 2,875.00
Over the past 30 years the biotechnology industry has evolved rapidly, resulting in changes to biopartnering dynamics. Out-licensors now command greater power and leverage over the licensing of their technologies, changing the approach of out-licensi...
|
USD $ 3,800.00
Introduction Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of...
|
USD $ 3,800.00
Introduction Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of...
|